ALL libraries (COBIB.SI union bibliographic/catalogue database)
  • 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma, imaging agent: first clinical experience
    Gmeiner, Tanja ...
    Objective This study was performed to explore the possibility of using 99mTc-rituximab as an imaging agent to assess expression of CD20 antigen in patients with B-cell non-Hodgkin's lymphoma (NHL) ... before (radio) immunotherapy, for staging and subsequent evaluation of remission of NHL. Methods Rituximab was purified from Mabthera and photoactivated by ultravioletlight. The irradiated solution was aliquoted and labelled with pertechnetate. The effectiveness of the labelling method was evaluated by determination of the number of free thiol groups per photoreduced antibody, radiochemical purity determination and in-vitro stability. Immunoreactivity of99mTc-rituximab was assessed on Ramos cells using a direct binding assay. Ten patients (age 31-70 years, mean 50 years) were included, nine with CD20+ B-cell NHL and one with CD20- NHL. Whole-body and single photon emission computed tomography images were taken 1, 3, 6 and 20 h postinjection of 99mTc-rituximab. Scintigraphic results were compared with computerized tomography (CT) findings. Results In all cases radiochemical purity over 95% was observed with preserved affinity for CD20 antigen. In all patients expected activity was seen in the blood pool, liver, kidneys and spleen. Pathological, moderately to markedly.
    Source: Nuclear medicine communications. - ISSN 0143-3636 (Vol. 29, no. 12, 2008, str. 1059-1065)
    Type of material - article, component part
    Publish date - 2008
    Language - english
    COBISS.SI-ID - 2380657
    DOI

source: Nuclear medicine communications. - ISSN 0143-3636 (Vol. 29, no. 12, 2008, str. 1059-1065)
loading ...
loading ...
loading ...